Ulcerative Colitis Market to Grow at 6.6% CAGR Driven By Rising Use of Biologics to 2020

PUNE, India, May 18, 2016 /PRNewswire/ --

The global ulcerative colitis market 2016 - 2020 research says a noteworthy trend to watch for in the pharmaceutical industry is the rising use of biologics. Biologics, available as either intravenous or subcutaneous injections, are increasingly becoming the treatment of choice for ulcerative colitis. They act by either blocking the interleukins or the tumor necrosis factor (TNF)-alpha. Etrolizumab, being developed by Genentech (Roche), and Stelara (ustekinumab), developed by Janssen Pharmaceuticals, are prominent biologics that are under investigation for the treatment of ulcerative colitis and are expected to be launched in ulcerative colitis market during the forecast period.

Complete report on ulcerative colitis market spread across 67 pages, analyzing 4 major companies and providing 44 data exhibits now available at http://www.reportsnreports.com/reports/541835-global-ulcerative-colitis-market-2016-2020.html

The analysts forecast global ulcerative colitis market to grow at a CAGR of 6.6% during the period 2016-2020.Key driver for ulcerative colitis market growth is the increase in patient assistance programs. Patients who cannot afford costly treatments are provided financial assistance by state and federal agencies such as Medicaid, Medicare, and Social Security in the US. People can also apply for free medications or financial co-pay assistance for the drug Humira through AbbVie's patient assistance program. According to the Humira Complete Savings Card, the drug can be obtained for as low as $5 per month. Similarly, Janssen Pharmaceuticals has initiated programs such as JanssenAccessOne and RemiStart.

The report covers the present scenario and the growth prospects of the global ulcerative colitis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used to treat ulcerative colitis. The Ulcerative Colitis Market is divided into the Following Segments Based on Geography: Americas, APAC and EMEA.

Global Ulcerative Colitis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key players in the global ulcerative colitis market: AbbVie, Janssen Biotech, Merck, and Takeda Pharmaceuticals. Other prominent vendors in the market are: Abbott, Ajinomoto Pharmaceuticals, Amgen, Arena Pharmaceuticals, AstraZeneca, Astellas Pharma, Avaxia Biologics, BioLineRx, Celgene, Cosmo Pharmaceuticals, Eisai, Ferring Pharmaceuticals, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Hutchison Medi Pharma, Immune Pharmaceuticals, InDex Pharmaceuticals, Kaken Pharmaceutical, Kissei Pharmaceutical, Kyowa Hakko Kirin, Lipid Therapeutics, Meda, Mitsubishi Tanabe, Mochida Pharmaceutical, Morphotek, Nestlé, Pfizer, Procter & Gamble, Qu Biologics, Receptos, Salix Pharmaceuticals, Shield Therapeutics, Shire Pharmaceuticals, Sterna Biologicals, Tillotts Pharma, TopiVert, UCB, and Zeria Pharmaceutical.

Further, the report states that expiring patents for many drugs will affect the bottom line for manufacturers and in turn, have an adverse impact on ulcerative colitis market growth. Order a copy of Global Ulcerative Colitis Market 2016-2020 report @ http://www.reportsnreports.com/Purchase.aspx?name=541835

Another related report is Global Inflammatory Bowel Disease Market 2015-2019, the analysts forecast global GERD drugs market to grow at a CAGR of 2.85% during the period 2016-2020. The dominance of the market by biologics used to treat patients suffering from the disease is one of the emerging trends. Biologics are expected to become a preferred treatment option for the medical fraternity, patients, and the families of patients during the forecast period.

Key players in the global inflammatory bowel disease market 2015-2019: AbbVie Inc., Biogen Idec Inc., Janssen Pharmaceuticals Inc., Merck & Co. Inc., Shire plc and UCB SA. Other prominent vendors in the market are: Amgen, Akebia Therapeutics, Boehringer Ingelheim, Celltrion, ChemoCentryx, Ferring Pharmaceuticals, Galapagos, Genentech, Mitsubishi Tanabe, Novartis, Novo Nordisk, Pfizer and Salix Pharmaceuticals. Browse complete report @ http://www.reportsnreports.com/reports/371232-global-inflammatory-bowel-disease-market-2015-2019-.html

Explore other new reports on Pharmaceuticals Market at http://www.reportsnreports.com/market-research/pharmaceuticals/.

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
[email protected]

Connect With Us on:

Facebook:  https://www.facebook.com/ReportsnReports/

LinkedIn:  https://www.linkedin.com/company/reportsnreports

Twitter:  https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports